Skip to main content
Back to Hillhouse Investment

Hillhouse Investment's Pharmaceutical Portfolio

Browse 7 Pharmaceutical companies funded by Hillhouse Investment. See funding amounts, founder contacts, and investment details.

Pharmaceutical Companies
7
Total Funding in Pharmaceutical
$59.7M

Pharmaceutical Portfolio Companies (7)

Export
BiotechnologyLife ScienceOncologyPharmaceutical

ArriVent develops pharmaceutical products to cure presently untreatable cancer.

Pennsylvania Furnace, United States
May 2026
Post-IPO Equity

Founder Contacts

19,000+ verified contacts

Artificial Intelligence (AI)BiotechnologyCosmeticsDietary SupplementsPharmaceutical

Metanovas develops drugs, dietary supplements, functional foods, and cosmetics using AI technology.

Mountain View, United States
March 2026
Series A

Founder Contacts

19,000+ verified contacts

BiopharmaBiotechnologyHealth CareMedicalPharmaceutical

Designing innovative technologies focused on accelerating global access to biotherapeutics.

Seattle, United States
January 2026
Grant

Founder Contacts

19,000+ verified contacts

BiotechnologyHealth CarePharmaceuticalTherapeutics

Arvinas advances therapies degrading disease-causing proteins for life-threatening diseases, from discovery to commercialization.

New Haven, United States
August 2025
Post Ipo Equity

Founder Contacts

19,000+ verified contacts

BiotechnologyHealth CareMedicalPharmaceutical

CStone Pharmaceuticals is a bio-pharmaceutical company develops new treatments in a range of therapeutic areas.

Suzhou, China
July 2025
$59.7M
Post Ipo Equity

Founder Contacts

19,000+ verified contacts

BiotechnologyOncologyPharmaceutical

IASO Biotherapeutics is a biopharmaceutical company focused on the development of cell therapies in the field of oncology.

Nanjing, China
July 2024
Corporate Round

Founder Contacts

19,000+ verified contacts

BiopharmaBiotechnologyGeneticsLife ScienceMedicalMedical DevicePharmaceuticalTherapeutics

HuidaGene is a global clinical-stage biotechnology company pioneering innovative gene therapies for neurology and ophthalmology.

Shanghai, China
May 2022
Series C

Founder Contacts

19,000+ verified contacts

Explore Hillhouse Investment's Full Portfolio

View all companies funded by Hillhouse Investment across every industry and funding stage.

View Full Hillhouse Investment Portfolio